288 related articles for article (PubMed ID: 15298014)
1. The errors of error testing: potential liability issues for medication error testing of pharmaceutical trademarks under U.S. law.
Thomas JA
Food Drug Law J; 2004; 59(2):325-37. PubMed ID: 15298014
[No Abstract] [Full Text] [Related]
2. Merck v. Integra: Supreme Court permits use of patented compounds to obtain Food and Drug Administration approvals.
Manthei JR; Hathaway CR; Grant MA; Chung DD
Food Drug Law J; 2006; 61(2):273-7. PubMed ID: 16903032
[No Abstract] [Full Text] [Related]
3. On access and accountability--two Supreme Court rulings on generic drugs.
Boumil MM; Curfman GD
N Engl J Med; 2013 Aug; 369(8):696-7. PubMed ID: 23923990
[No Abstract] [Full Text] [Related]
4. The application of the patent laws to the drug approval process.
Coggio BD; Cerrito FD
Food Drug Law J; 1997; 52(4):345-55. PubMed ID: 10346669
[No Abstract] [Full Text] [Related]
5. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
Dinh TQ
Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
[No Abstract] [Full Text] [Related]
6. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
McPhie DC
Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
[No Abstract] [Full Text] [Related]
7. Enterprise liability for bad outcomes from drug therapy: the doctor, the hospital, the pharmacy, and the drug firm.
Furrow BR
Spec Law Dig Health Care Law; 1998 Apr; (229):9-69. PubMed ID: 10178162
[No Abstract] [Full Text] [Related]
8. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
McCabe AR
Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
[No Abstract] [Full Text] [Related]
9. US courts narrow patent exemptions.
Fox JL
Nat Biotechnol; 2003 Aug; 21(8):834. PubMed ID: 12894182
[No Abstract] [Full Text] [Related]
10. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
Gitter DM
Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
[No Abstract] [Full Text] [Related]
11. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
Soehnge H
Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
[No Abstract] [Full Text] [Related]
12. Realizing two-tiered innovation policy through drug regulation.
Ridgway WE
Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
[No Abstract] [Full Text] [Related]
13. Lawsuits anticipated on generic biologicals front.
Fox JL
Nat Biotechnol; 2003 Jul; 21(7):721-2. PubMed ID: 12833078
[No Abstract] [Full Text] [Related]
14. Branded drug reformulation: the next brand vs. generic antitrust battleground.
Amoresano GV
Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
[No Abstract] [Full Text] [Related]
15. Analysis of the impact of the Uruguay Round Agreements Act on pharmaceutical patents.
Seoane-Vazquez E; Rodriguez-Monguio R; Szeinbach SL; Beyer A; Visaria J
Food Drug Law J; 2009; 64(1):171-81. PubMed ID: 19998745
[TBL] [Abstract][Full Text] [Related]
16. [Legal liability in clinical trials from the legal-pharmaceutical viewpoint].
Amon F
Z Arztl Fortbild (Jena); 1995 Nov; 89(6):638-41. PubMed ID: 8588437
[TBL] [Abstract][Full Text] [Related]
17. Compulsory licensing to regulated licensing: effects on the conflict between innovation and access in the pharmaceutical industry.
Gillat A
Food Drug Law J; 2003; 58(4):711-40. PubMed ID: 15027457
[No Abstract] [Full Text] [Related]
18. Preparing effective experimental data for pharmaceutical patent applications from US and Japanese perspectives.
Altman D; Sweeney C; Yasui T
Pharm Pat Anal; 2014 Sep; 3(5):469-73. PubMed ID: 25374314
[No Abstract] [Full Text] [Related]
19. Staving off death: a case study of the pharmaceutical industry's strategies to protect blockbuster franchises.
Gorlin DI
Food Drug Law J; 2008; 63(4):823-64. PubMed ID: 19601385
[No Abstract] [Full Text] [Related]
20. Navigating the Hatch-Waxman Act's safe harbor.
Jones PB
Food Drug Law J; 2002; 57(3):475-89. PubMed ID: 12710407
[No Abstract] [Full Text] [Related]
[Next] [New Search]
